Female teenager holding a bottle of TWYNEO cream playfully in front of her face.

Potent doses combined with skin in mind

Not an actual patient.

∼90% of patients who used TWYNEO cream in clinical studies stayed on therapy through Week 121-3

Table with most common adverse reactions.

Less than 3%of patients in active arm discontinued due to adverse reactions.2,3

Less than 1%of patients had a severe adverse reaction.2,3

Table with most common facial cutaneous adverse reactions.

TWYNEO cream was tolerable with transient effects over time.1

Line graph measuring erythema, scaling, and dryness overtime from baseline to Week 12, with scores peaking at Week 2.
A line graph measuring itching, burning, and stinging overtime from baseline to Week 12, with scores peaking at Week 2.

*

Local tolerability signs and symptoms were evaluated on a 4-point severity scale: 0 (none), 1 (mild), 2 (moderate), and 3 (severe) from baseline to Week 12—all scores stayed below 1 through Week 12.2,3

References: 1. TWYNEO (tretinoin and benzoyl peroxide) cream, 0.1%/3% [Prescribing Information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2021. 2. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-65-04; May 28, 2020. 3. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-65-05; June 5, 2020.

× Table with most common adverse reactions.
× Table with most common facial cutaneous adverse reactions.
× Line graph measuring erythema, scaling, and dryness overtime from baseline to Week 12, with scores peaking at Week 2.
× A line graph measuring itching, burning, and stinging overtime from baseline to Week 12, with scores peaking at Week 2.